Compulsory Bioequivalence Testing Requirement under Further Deliberation

Published: 2005-02-25 06:57:00

Updated: 2005-02-25 06:57:00

As the industry constituents has essentially reached a general consensus on the enforcement of small-unit packaging requirement for pharmaceutical products in a periodic rollout scheme, the compulsory bioequivalence testing requirement for generic drugs is deemed as the major point at issue.

O...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK